Cytokine Autoantibody Screening in the Swedish Addison Registry Identifies Patients With Undiagnosed APS1.Uppsala University, Uppsala, Sweden.
Karolinska Institutet, Stockholm, Uppsala University, Uppsala, Sweden.
Umeå University, Umeå, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Department of Endocrinology. Linköping University, Department of Clinical and Experimental Medicine.
Sahlgrenska Academy, University of Gothenburg, Gothenburg.
Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet, Stockholm, Sweden.
Uppsala University, Uppsala, Sweden.
Karolinska Institutet, Stockholm, Sweden.
Uppsala University, Uppsala, Sweden, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Uppsala University, Uppsala, Sweden.
Karolinska Institutet, Stockholm, University of Bergen, Bergen, K.G. Jebsen Center for Autoimmune Disorders, Bergen, Norway.
University of Bergen, Bergen, Haukeland University Hospital, Bergen, Norway.
Uppsala University, Uppsala, Sweden.
Karolinska University Hospital, Stockholm, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet, Stockholm, Karolinska University Hospital, Stockholm, Uppsala University, Uppsala, Sweden, K.G. Jebsen Center for Autoimmune Disorders, Bergen, Norway.
Show others and affiliations
2018 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 103, no 1, p. 179-186Article in journal (Refereed) Published
Abstract [en]
Context: Autoimmune polyendocrine syndrome type 1 (APS1) is a monogenic disorder that features autoimmune Addison disease as a major component. Although APS1 accounts for only a small fraction of all patients with Addison disease, early identification of these individuals is vital to prevent the potentially lethal complications of APS1.
Objective: To determine whether available serological and genetic markers are valuable screening tools for the identification of APS1 among patients diagnosed with Addison disease.
Design: We systematically screened 677 patients with Addison disease enrolled in the Swedish Addison Registry for autoantibodies against interleukin-22 and interferon-α4. Autoantibody-positive patients were investigated for clinical manifestations of APS1, additional APS1-specific autoantibodies, and DNA sequence and copy number variations of AIRE.
Results: In total, 17 patients (2.5%) displayed autoantibodies against interleukin-22 and/or interferon-α4, of which nine were known APS1 cases. Four patients previously undiagnosed with APS1 fulfilled clinical, genetic, and serological criteria. Hence, we identified four patients with undiagnosed APS1 with this screening procedure.
Conclusion: We propose that patients with Addison disease should be routinely screened for cytokine autoantibodies. Clinical or serological support for APS1 should warrant DNA sequencing and copy number analysis of AIRE to enable early diagnosis and prevention of lethal complications.
Place, publisher, year, edition, pages
2018. Vol. 103, no 1, p. 179-186
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:liu:diva-144202DOI: 10.1210/jc.2017-01957ISI: 000424934300021PubMedID: 29069385OAI: oai:DiVA.org:liu-144202DiVA, id: diva2:1172534
Note
Funding agencies: Swedish Research Council; Torsten Soderberg Foundation; Ragnar Soderberg Foundation; European Union Seventh Framework Programme [201167]; Stockholm County Council; Karolinska Institutet; Swedish Society for Medical Research; Swedish Society of Medicine; N
2018-01-102018-01-102019-05-01